The U.S. Food and Drug Administration has given Bristol-Myers Squibb Co.’s Devens biomanufacturing plant in Devens the go-ahead to begin producing the rheumatoid arthritis-fighting drug Orencia for commercial distribution.
The Devens facility employs about 300 workers. The company completed the $750 million plant in 2009 and has been preparing for commercial production ever since.
Bristol-Myers said it will also continue manufacturing at its current production site in Syracuse, N.Y., which will serve as a center of excellence in process development.
